Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.33 |
| ▸ | EIF4E | P06730 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30462807 | 1.00 | FFAR1 (0.38) | FFAR1FFAR4KCNH2TMEM97SIGMAR1 | |
| SCHEMBL4349038 | 0.84 | PKM (0.46) | KCNH2TMEM97SIGMAR1HTR2AHTR2C | |
| SCHEMBL3819565 | 0.82 | RXRA (0.41) | FFAR1FFAR4KCNH2PKMALDH1A1 | |
| SCHEMBL30019983 | 0.82 | RXRA (0.41) | FFAR1FFAR4KCNH2PKMALDH1A1 | |
| SCHEMBL12635127 | 0.80 | FFAR1 (0.40) | FFAR1FFAR4PKM | |
| SCHEMBL8275570 | 0.80 | FFAR1 (0.40) | FFAR1FFAR4PKM | |
| SCHEMBL11916155 | 0.79 | HTR1A (0.41) | KCNH2TMEM97SIGMAR1HTR2AACLY | |
| SCHEMBL4071668 | 0.79 | FFAR1 (0.36) | FFAR1FFAR4HTR2AHTR2CPKM | |
| SCHEMBL12134877 | 0.79 | KMT2A (0.50) | FFAR1FFAR4HTR2AHTR2CHTR2B | |
| SCHEMBL12635108 | 0.79 | KMT2A (0.50) | FFAR1FFAR4HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522619-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4463462-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | Annexon, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2023-08-24 | — | — | US | disclosed |
| WO-2023137166-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023137166-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| US-7470711-B2 | Piperidinyl substituted cyclohexane-1,4-diamines | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-30 | — | — | US | disclosed |
| US-7470711-B2 | Piperidinyl substituted cyclohexane-1,4-diamines | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-30 | — | — | US | disclosed |
| US-7470711-B2 | Piperidinyl substituted cyclohexane-1,4-diamines | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-30 | — | — | US | disclosed |
| US-20080221163-A1 | Selective Estrogen Receptor Modulators | ELI LILLY AND COMPANY | 2008-09-11 | — | — | US | disclosed |
| CN-101180057-A | Piperidinyl substituted cyclohexane-1,4-diamines | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-14 | — | — | CN | disclosed |
| EP-1865956-A2 | PIPERIDINYL SUBSTITUTED CYCLOHEXANE-1,4-DIAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-19 | — | — | EP | disclosed |
| EP-1713820-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2006101859-A2 | PIPERIDINYL SUBSTITUTED CYCLOHEXANE-1,4-DIAMINES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-09-28 | — | — | WO | disclosed |
| US-20060217419-A1 | Piperidinyl substituted cyclohexane-1,4-diamines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-09-28 | — | — | US | disclosed |
| WO-2005073244-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217419-A1 | Piperidinyl substituted cyclohexane-1,4-diamines | ADRA1D, ADRA1A, ADRB1 | FFAR1 173/4885FFAR4 434/4885KCNH2 1276/4885 |
| US-20080221163-A1 | Selective Estrogen Receptor Modulators | GPER1, ESR2, ESR1 | FFAR1 65/4885FFAR4 233/4885KCNH2 2276/4885 |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | FFAR1 1038/4885FFAR4 1159/4885KCNH2 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.